CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   995 Trials   3123 News 


«12...3839404142434445464748...5253»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    Journal:  Anti-PD-1 plus a VEGFR2 Inhibitor Shows Promise in Cervical Cancer. (Pubmed Central) -  Oct 26, 2020   
    Camrelizumab demonstrated high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting. The PD-1 antibody camrelizumab plus the VEGFR2 inhibitor apatinib had efficacy in a phase II trial.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) -  Oct 22, 2020   
    P2,  N=40, Completed, 
    The PD-1 antibody camrelizumab plus the VEGFR2 inhibitor apatinib had efficacy in a phase II trial. Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Aug 2019 --> Dec 2019
  • ||||||||||  luxeptinib (CG-806) / Aptose Biosci
    Enrollment open, Trial initiation date:  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS (clinicaltrials.gov) -  Oct 22, 2020   
    P1/2,  N=80, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Aug 2019 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Jul 2020 --> Oct 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors () -  Oct 14, 2020 - Abstract #SITC2020SITC_1217;    
    Among the 33 patients, 5 patients had immune-related adverse reactions (15.2%), including 2 cases of skin rash, 1 case of skin capillary hyperplasia and 2 cases of other adverse reactions. Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors () -  Oct 14, 2020 - Abstract #SITC2020SITC_482;    
    Among the 33 patients, 5 patients had immune-related adverse reactions (15.2%), including 2 cases of skin rash, 1 case of skin capillary hyperplasia and 2 cases of other adverse reactions. Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC (clinicaltrials.gov) -  Oct 12, 2020   
    P1/2,  N=53, Recruiting, 
    Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy. Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial:  Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Oct 11, 2020   
    P2,  N=42, Not yet recruiting, 
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] A realworld clinical study of camrelizumab in the treatment of esophageal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1024;    
    The grade 3/4 treatment-related AEs were RCCEP (1.0%), hypothyroidism (1.0%) and anemia(1.0%). In real clinical applications, Camrelizumab is mostly used in patients with poor physical condition, metastatic and late stage, and most patients had front-line treatment.PD-L-1 detection is rarely performed in patients before medication, and most patients are treated with combination therapy of Camrelizumab.Camrelizumab is confirmed to be effective and safe in patients with esophageal cancer.Further analysis is needed to determine which factors are the positive factors in the treatment of Camrelizumab.
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] A realworld clinical study of camrelizumab in the treatment of esophageal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_658;    
    The grade 3/4 treatment-related AEs were RCCEP (1.0%), hypothyroidism (1.0%) and anemia(1.0%). In real clinical applications, Camrelizumab is mostly used in patients with poor physical condition, metastatic and late stage, and most patients had front-line treatment.PD-L-1 detection is rarely performed in patients before medication, and most patients are treated with combination therapy of Camrelizumab.Camrelizumab is confirmed to be effective and safe in patients with esophageal cancer.Further analysis is needed to determine which factors are the positive factors in the treatment of Camrelizumab.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker:  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy. (Pubmed Central) -  Oct 3, 2020   
    Additional checkpoint inhibitors including nivolumab, durvalumab, atezolizumab, and camrelizumab are in different stages of clinical development for the disease. Finally, an additional targeted approach being pursued involves PARP inhibitors (rucaparib and olaparib are both in Phase II) based on earlier study results.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial initiation date, Trial primary completion date:  PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (clinicaltrials.gov) -  Sep 28, 2020   
    P2,  N=65, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2020 --> Dec 2020 Trial completion date: Dec 2022 --> Feb 2024 | Initiation date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2021 --> Aug 2022
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma (clinicaltrials.gov) -  Sep 28, 2020   
    P2,  N=51, Recruiting, 
    Trial completion date: Dec 2022 --> Feb 2024 | Initiation date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2021 --> Aug 2022 Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Dec 2022 | Initiation date: Nov 2019 --> May 2020 | Trial primary completion date: Jan 2022 --> May 2022
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] TREATMENT RELATED ADVERSE EVENTS PREDICT BETTER PROGRESSION FREE SURVIVAL FOR HCC UNDERWENT ANTI-PD-1 THERAPY () -  Sep 24, 2020 - Abstract #ILCA2020ILCA_217;    
    TRAEs that occurred in more than 10% of patients were reactive capillary hemangiomas in 15 patients (88.2% in patients received Camrelizumab, while 32.6% in all patients), liver dysfunction in 15(32.6%) patients, thyroid dysfunction in 9(19.6%) patients, rash in 6(13%) patients, amylase increase in 5(10.9%) patients, hemocytopenia in 5(10.9%) patients... Treatment related adverse events and vascular invasion were independent prognostic factors for PFS in HCC underwent anti-PD-1 therapy.